Cargando…
Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer
BACKGROUND: TGF-β plays a dual role in the progression of human cancer. During the early stages of carcinogenesis, TGF-β functions as a tumor suppressor. During the late stages of tumor development, however, TGF-β can promote tumor growth and metastasis. A shift in Smad2/3 phosphorylation from the c...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334357/ https://www.ncbi.nlm.nih.gov/pubmed/22539990 http://dx.doi.org/10.1371/journal.pone.0035684 |
_version_ | 1782230625756905472 |
---|---|
author | Wu, Yijun Li, Qi Zhou, Xinhui Yu, Jiren Mu, Yunchuan Munker, Stefan Xu, Chengfu Shen, Zhe Müllenbach, Roman Liu, Yan Li, Li Gretz, Norbert Zieker, Derek Li, Jun Matsuzaki, Kouichi Li, Youming Dooley, Steven Weng, Honglei |
author_facet | Wu, Yijun Li, Qi Zhou, Xinhui Yu, Jiren Mu, Yunchuan Munker, Stefan Xu, Chengfu Shen, Zhe Müllenbach, Roman Liu, Yan Li, Li Gretz, Norbert Zieker, Derek Li, Jun Matsuzaki, Kouichi Li, Youming Dooley, Steven Weng, Honglei |
author_sort | Wu, Yijun |
collection | PubMed |
description | BACKGROUND: TGF-β plays a dual role in the progression of human cancer. During the early stages of carcinogenesis, TGF-β functions as a tumor suppressor. During the late stages of tumor development, however, TGF-β can promote tumor growth and metastasis. A shift in Smad2/3 phosphorylation from the carboxy terminus to linker sites is a key event determining biological function of TGF-β in colorectal and hepatocellular carcinoma. In the present study, we investigated the potential role of differential Smad2/3 phosphorylation in gastric adenocarcinoma. METHODOLOGY: Immunohistochemical staining with anti-P-Smad2/3C and P-Smad2/3L antibodies was performed on 130 paraffin-embedded gastric adenocarcinoma specimens. The relationship between P-Smad2/3C and P-Smad2/3L immunohistochemical score and clinicopathologic characteristics of patients was analyzed. Real time PCR was used to measure mRNA expression of Smad2 and Smad3 in cancer and surrounding non-tumor tissue. PRINCIPAL FINDINGS: No significant P-Smad2L and/or P-Smad3L positive staining was detected in the majority of specimens (positive staining in 18/130 samples). Positive P-Smad2/3L staining was not associated with a decrease in carboxyterminal phosphorylation staining. Loss of P-Smad2C remarkably correlated with depth of tumor infiltration and poor differentiation of cancer cells in patients with gastric cancer. No correlation was detectable between P-Smad3C and clinicopathologic characteristics of gastric adenocarcinoma. However, co-staining analysis revealed that P-Smad3C co-localised with α-SMA and collagen I in gastric cancer cells, indicating a potential link between P-Smad3C and epithelial-to-mesenchymal transition of cancer. Real time PCR demonstrated reduced mRNA expression of Smad2 in gastric cancer when compared with surrounding non-tumor tissue in 15/16 patients. CONCLUSIONS: Loss of P-Smad2C tightly correlated with cancer invasion and poor differentiation in gastric cancer. Contrary to colorectal and hepatocellular carcinoma, canonical carboxy-terminal phosphorylation, but not linker phosphorylation, of Smad2 is critical for gastric cancer. |
format | Online Article Text |
id | pubmed-3334357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33343572012-04-26 Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer Wu, Yijun Li, Qi Zhou, Xinhui Yu, Jiren Mu, Yunchuan Munker, Stefan Xu, Chengfu Shen, Zhe Müllenbach, Roman Liu, Yan Li, Li Gretz, Norbert Zieker, Derek Li, Jun Matsuzaki, Kouichi Li, Youming Dooley, Steven Weng, Honglei PLoS One Research Article BACKGROUND: TGF-β plays a dual role in the progression of human cancer. During the early stages of carcinogenesis, TGF-β functions as a tumor suppressor. During the late stages of tumor development, however, TGF-β can promote tumor growth and metastasis. A shift in Smad2/3 phosphorylation from the carboxy terminus to linker sites is a key event determining biological function of TGF-β in colorectal and hepatocellular carcinoma. In the present study, we investigated the potential role of differential Smad2/3 phosphorylation in gastric adenocarcinoma. METHODOLOGY: Immunohistochemical staining with anti-P-Smad2/3C and P-Smad2/3L antibodies was performed on 130 paraffin-embedded gastric adenocarcinoma specimens. The relationship between P-Smad2/3C and P-Smad2/3L immunohistochemical score and clinicopathologic characteristics of patients was analyzed. Real time PCR was used to measure mRNA expression of Smad2 and Smad3 in cancer and surrounding non-tumor tissue. PRINCIPAL FINDINGS: No significant P-Smad2L and/or P-Smad3L positive staining was detected in the majority of specimens (positive staining in 18/130 samples). Positive P-Smad2/3L staining was not associated with a decrease in carboxyterminal phosphorylation staining. Loss of P-Smad2C remarkably correlated with depth of tumor infiltration and poor differentiation of cancer cells in patients with gastric cancer. No correlation was detectable between P-Smad3C and clinicopathologic characteristics of gastric adenocarcinoma. However, co-staining analysis revealed that P-Smad3C co-localised with α-SMA and collagen I in gastric cancer cells, indicating a potential link between P-Smad3C and epithelial-to-mesenchymal transition of cancer. Real time PCR demonstrated reduced mRNA expression of Smad2 in gastric cancer when compared with surrounding non-tumor tissue in 15/16 patients. CONCLUSIONS: Loss of P-Smad2C tightly correlated with cancer invasion and poor differentiation in gastric cancer. Contrary to colorectal and hepatocellular carcinoma, canonical carboxy-terminal phosphorylation, but not linker phosphorylation, of Smad2 is critical for gastric cancer. Public Library of Science 2012-04-23 /pmc/articles/PMC3334357/ /pubmed/22539990 http://dx.doi.org/10.1371/journal.pone.0035684 Text en Wu et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Wu, Yijun Li, Qi Zhou, Xinhui Yu, Jiren Mu, Yunchuan Munker, Stefan Xu, Chengfu Shen, Zhe Müllenbach, Roman Liu, Yan Li, Li Gretz, Norbert Zieker, Derek Li, Jun Matsuzaki, Kouichi Li, Youming Dooley, Steven Weng, Honglei Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title | Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title_full | Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title_fullStr | Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title_full_unstemmed | Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title_short | Decreased Levels of Active SMAD2 Correlate with Poor Prognosis in Gastric Cancer |
title_sort | decreased levels of active smad2 correlate with poor prognosis in gastric cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334357/ https://www.ncbi.nlm.nih.gov/pubmed/22539990 http://dx.doi.org/10.1371/journal.pone.0035684 |
work_keys_str_mv | AT wuyijun decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT liqi decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT zhouxinhui decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT yujiren decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT muyunchuan decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT munkerstefan decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT xuchengfu decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT shenzhe decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT mullenbachroman decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT liuyan decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT lili decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT gretznorbert decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT ziekerderek decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT lijun decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT matsuzakikouichi decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT liyouming decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT dooleysteven decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer AT wenghonglei decreasedlevelsofactivesmad2correlatewithpoorprognosisingastriccancer |